News

US FDA approves PTC Therapeutics' metabolic disorder drug
The U.S. Food and Drug Administration has approved PTC Therapeutics' oral drug to treat a rare inherited metabolic disorder ...
Leerink Partners Maintains a Buy on BioMarin Pharmaceutical (BMRN), Retains a $105 PT
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the most profitable biotech stocks to invest in now. On July 23, analyst ...
EconoTimes1d
FDA Approves PTC Therapeutics’ Sephience for Rare Genetic Disorder PKU
The U.S. Food and Drug Administration (FDA) has approved PTC Therapeutics (NASDAQ:PTCT) oral drug Sephience to treat ...
India Today1d
US FDA approves new oral drug for rare genetic disorder phenylketonuria
The FDA approved PTC Therapeutics' new oral drug Sephience for treating phenylketonuria, a rare genetic disorder. It offers a new option as existing treatments face limitations and revenue declines.
BioMarin: Less Likely M&A Target As New Rival For Best-Selling Drug Emerges (Rating Downgrade)
Ascendis’ likely approval of TransCon CNP for achondroplasia poses a major threat to BioMarin’s best-selling drug. Read why I ...